| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2025―Feb―11 |
Microbiome and mycobiome cross-talk from an immunobiotic perspective in COVID-19 and post-acute COVID-19 syndrome |
Sunny Kumar, Zeel Bhatia, Sriram Seshadri |
| 2 |
[GO] |
2025―Jan―23 |
Factors associated with the formation of neutralizing antibodies post-vaccination: a lesson from COVID-19 vaccination |
Hana Ratnawati, Fen Tih, Grace Puspasari, Allen A. Pelapelapon, Steven Felim |
| 3 |
[GO] |
2024―Oct―30 |
Durability of SARS-CoV-2 IgG response: a cross-sectional study in vaccinated healthcare workers using dried blood spot and multi-antigen profiling |
Imam Nurjaya, Erwin Arief, Nur Ahmad Tabri, Irawaty Djaharuddin, Bulkis Natsir, Sitti Nurisyah, et al. (+4) Joko Hendarto, Ansariadi Ansariadi, Rasiha Rasiha, Moh. Anfasa Giffari Makkaraka |
| 4 |
[GO] |
2024―May―17 |
The immune response of nano carbon-based photic-driving vaccines to severe acute respiratory syndrome coronavirus 2 |
Junming Chen, Qiang Wang, Fenfen Zhang, Jianshe Yang |
| 5 |
[GO] |
2024―Apr―18 |
Physical activity, immune system and hypertension: reflections and challenges for future pandemics based on learning from coronavirus disease 2019 |
Francisco Pitanga |
| 6 |
[GO] |
2024―Feb―29 |
Myelitis associated with COVID-19: clinical, radiological, and laboratory characteristics |
Aleksandra Kozlova, Alina Dzharullaeva, Amir Tukhvatulin, Inessa Zakroyshchikova, Taras Simaniv, Lola Askarova, et al. (+5) Daria Eliseeva, Natalia Stoida, Ivan Kochergin, Ekaterina Baydina, Maria Zakharova |
| 7 |
[GO] |
2024―Jan―31 |
Paradigm of immune dysregulation in coronavirus disease-2019 infection |
Om Saswat Sahoo, Karthikeyan Pethusamy, Arnab Nayek, Rashmi Minocha, Ruby Dhar, Subhradip Karmakar |
| 8 |
[GO] |
2023―Oct―16 |
Loss of regulation of T helper 17 cells: a definitive factor for critical cases of coronavirus disease 2019 |
Miguel Angel Pardiño-Vega, Norma Estela Herrera-González |
| 9 |
[GO] |
2023―Oct―11 |
Effect of coronavirus disease 2019 on the vaccine development paradigm |
Sezer Okay |
| 10 |
[GO] |
2023―Aug―24 |
Trained-immunity and cross-reactivity for protection: insights from the coronavirus disease 2019 and monkeypox emergencies for vaccine development |
Amanda Izeli Portilho, Elizabeth De Gaspari |
| 11 |
[GO] |
2023―Aug―04 |
COVID-19 induced ARDS: immunopathology and therapeutics |
Sneha Das, Tamanna Sharma, Asha Bhardwaj, Rupesh K. Srivastava |
| 12 |
[GO] |
2023―Mar―01 |
SARS-CoV-2 infection activates the cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes pathway in the lung: a review |
Gislei F. Aragão, Sthefane G. Feitosa, Herlice Do Nascimento Veras, Cícero Gilmário A. P. de Lima Filho, Karinne da S. Assunção, Luana M. Arrais, Sara Lívia M. Teixeira |
| 13 |
[GO] |
2023―Feb―27 |
Innate immune cell and severe acute respiratory syndrome coronavirus 2 interaction |
Naima G. Cortes-Perez |
| 14 |
[GO] |
2022―Sep―21 |
Immune responses to SARS-CoV-2 infection and COVID-19 vaccines |
Basista Rabina Sharma, P. Veeranna Ravindra |
| 15 |
[GO] |
2022―Aug―26 |
Immune network operations in COVID-19 |
Javier Burgos-Salcedo |
| 16 |
[GO] |
2022―Aug―11 |
Small molecules targeting endolysosomal acidification and signaling in sepsis and severe SARS-CoV-2 infection/COVID-19 |
Markus Blaess, Oliver Sommerfeld, René Csuk, Hans-Peter Deigner |
| 17 |
[GO] |
2022―Jul―18 |
In COVID-19, antigen size lower or larger than 70 kDa modulates the sepsis and memory B cells |
Francisco Javier Martín Oncina |
| 18 |
[GO] |
2022―May―17 |
SARS-CoV-2: overview of immune response, insights into vaccine platforms and their challenges |
Balram Ji Omar, Arpana Singh, Vanya Singh, Ashish Kothari, Manju O. Pai |
| 19 |
[GO] |
2022―Mar―16 |
High avidity of vaccine-induced immunoglobulin G against SARS-CoV-2: potential relevance for protective humoral immunity |
Georg Bauer |
| 20 |
[GO] |
2022―Feb―11 |
Immune titers of protection against severe acute respiratory syndrome coronavirus 2: are we there yet? |
Yoanna Slabakova, Dilyana Gerenska, Nedelcho Ivanov, Tsvetelina Velikova |
| 21 |
[GO] |
2021―Dec―31 |
State-of-the-art preclinical evaluation of COVID-19 vaccine candidates |
Devlina Ghosh, Bingxin Bai, Qun Ji, Soumya Palliyil, Guang Yang, Alok Kumar, Abhishek Saxena |
| 22 |
[GO] |
2021―Dec―31 |
New variants of SARS-CoV-2, vaccine immune response and the Brazilian reality |
Marileia Andrade, Luiza Gomes, Vitória Mendes, Hellen Rosa |
| 23 |
[GO] |
2021―Dec―14 |
Activation of mucosal immunity and novel prophylactic and therapeutic strategy in combating COVID-19 |
Swapan K. Chatterjee, Snigdha Saha, Maria Nilda M. Munoz |
| 24 |
[GO] |
2021―Dec―13 |
COVID-19 vaccine and immune response |
Sevilay Hintistan, Hatice Demirağ |
| 25 |
[GO] |
2021―Dec―10 |
Vaccine-induced immune responses against SARS-CoV-2 infections |
Mandeep Garg, Muniraju Maralakunte, Yashwant Kumar, Harish Bhujade, Inder Paul Sehgal, Vikas Suri, Suruchi Garg |
| 26 |
[GO] |
2021―Nov―01 |
Viral vector-based vaccines against SARS-CoV-2 |
Kenneth Lundstrom |
| 27 |
[GO] |
2021―Sep―30 |
Immune responses induced by different vaccine platforms against coronavirus disease-19 |
Eknath D. Ahire, Sanjay J Kshirsagar |
| 28 |
[GO] |
2021―Sep―01 |
Severe acute respiratory syndrome coronavirus 2 targeted antibodies cocktail and B cell receptor interplay: interventions to trigger vaccine development |
Kabeer Haneef, Rabia Saleem, Muhammad Saleem Iqbal Khan, Olawale Samuel Adeyinka, Sadeeq Banday, Muhammad Umer Asghar, et al. (+2) Zia Ur Rahman, Zainab Fatima |
| 29 |
[GO] |
2021―Sep―01 |
The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal |
Eduardo Tosta |
| 30 |
[GO] |
2021―Sep―01 |
Conserved envelope protein of nCoV2 as the possible target to design polytope vaccine |
Krupanidhi Sreerama |
| 31 |
[GO] |
2021―Jul―01 |
Immunopathogenesis of severe acute respiratory syndrome coronavirus-2: evolving knowledge and its current status |
Nitin Saksena, Srinivasa Reddy Bonam, Monica Miranda-Saksena |
| 32 |
[GO] |
2021―Mar―31 |
In silico investigation of binding affinities between human leukocyte antigen class I molecules and SARS-CoV-2 virus spike and ORF1ab proteins |
Spyros A. Charonis, Effie-Photini Tsilibary, Apostolos P. Georgopoulos |
